We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag
Read MoreHide Full Article
Pfizer (PFE - Free Report) announced that the FDA granted fast-track designation to its early-stage mRNA-based vaccine candidate targeting influenza and COVID-19. The vaccine is being developed in collaboration with BioNTech (BNTX - Free Report) .
Fast Track is designed to facilitate the development and acceleration of the review of drugs to treat serious conditions and fill an unmet medical need or offer a potential advantage over the existing treatments. A candidate granted Fast Track designation is also eligible for rolling review.
The vaccine is a combination of Pfizer/BioNTech’s authorized Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine and their investigational quadrivalent modRNA-based influenza vaccine. It is currently being evaluated in a phase III study.
Shares of Pfizer have lost 6.3% in the year so far against the industry’s 16.3% rise.
Image Source: Zacks Investment Research
Last month, Pfizer and BioNTech initiated a phase I study to evaluate the safety, tolerability, and immunogenicity of this COVID-19/influenza combination vaccine in 180 healthy study participants aged 18 through 64 years.
Through their combination vaccine, Pfizer/BioNTech aim to simplify immunization practices against two respiratory diseases caused by evolving viruses that require vaccine adaptation.
Like Pfizer/BioNTech, several other companies like Moderna (MRNA - Free Report) and Novavax (NVAX - Free Report) are also developing their combination vaccines targeting both influenza and COVID-19 indications in early-stage development.
Moderna is evaluating mRNA-1073, its own mRNA-based combination vaccine, in a phase I/II study. mRNA-1073 is a combination of Spikevax (mRNA-1273), Moderna’s approved/authorized COVID-19 vaccine, and mRNA-1010, an investigational flu vaccine currently in phase III development. Moderna’s phase I/II study is evaluating mRNA-1073 to co-administered mRNA-1010 and mRNA-1273 and to mRNA-1010 and mRNA-1273 administered alone.
Novavax is also evaluating a COVID-19-influenza combination (CIC) vaccine candidate in a phase I/II study. The CIC vaccine combines NVX-CoV2373, its authorized protein-based COVID vaccine, and its investigational influenza vaccine in a single formulation. In October, Novavax announced top-line data from this study which demonstrated the CIC vaccine was feasible and immunogenic. The immune responses were comparable to the standalone influenza vaccine candidate and standalone NVX-CoV2373 formulations. Novavax expects to begin a confirmatory phase II study evaluating this vaccine by this year’s end.
Image: Bigstock
Pfizer (PFE), BNTX's COVID-Flu Combo Jab Gets FDA Fast Track Tag
Pfizer (PFE - Free Report) announced that the FDA granted fast-track designation to its early-stage mRNA-based vaccine candidate targeting influenza and COVID-19. The vaccine is being developed in collaboration with BioNTech (BNTX - Free Report) .
Fast Track is designed to facilitate the development and acceleration of the review of drugs to treat serious conditions and fill an unmet medical need or offer a potential advantage over the existing treatments. A candidate granted Fast Track designation is also eligible for rolling review.
The vaccine is a combination of Pfizer/BioNTech’s authorized Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine and their investigational quadrivalent modRNA-based influenza vaccine. It is currently being evaluated in a phase III study.
Shares of Pfizer have lost 6.3% in the year so far against the industry’s 16.3% rise.
Image Source: Zacks Investment Research
Last month, Pfizer and BioNTech initiated a phase I study to evaluate the safety, tolerability, and immunogenicity of this COVID-19/influenza combination vaccine in 180 healthy study participants aged 18 through 64 years.
Through their combination vaccine, Pfizer/BioNTech aim to simplify immunization practices against two respiratory diseases caused by evolving viruses that require vaccine adaptation.
Like Pfizer/BioNTech, several other companies like Moderna (MRNA - Free Report) and Novavax (NVAX - Free Report) are also developing their combination vaccines targeting both influenza and COVID-19 indications in early-stage development.
Moderna is evaluating mRNA-1073, its own mRNA-based combination vaccine, in a phase I/II study. mRNA-1073 is a combination of Spikevax (mRNA-1273), Moderna’s approved/authorized COVID-19 vaccine, and mRNA-1010, an investigational flu vaccine currently in phase III development. Moderna’s phase I/II study is evaluating mRNA-1073 to co-administered mRNA-1010 and mRNA-1273 and to mRNA-1010 and mRNA-1273 administered alone.
Novavax is also evaluating a COVID-19-influenza combination (CIC) vaccine candidate in a phase I/II study. The CIC vaccine combines NVX-CoV2373, its authorized protein-based COVID vaccine, and its investigational influenza vaccine in a single formulation. In October, Novavax announced top-line data from this study which demonstrated the CIC vaccine was feasible and immunogenic. The immune responses were comparable to the standalone influenza vaccine candidate and standalone NVX-CoV2373 formulations. Novavax expects to begin a confirmatory phase II study evaluating this vaccine by this year’s end.
Pfizer Inc. Price
Pfizer Inc. price | Pfizer Inc. Quote
Zacks Rank
Pfizer currently carries a Zacks Rank #3 (Hold).You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.